| Nome |
# |
|
PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients, file de3e52b0-f2a5-762d-e053-3705fe0a30e0
|
44
|
|
Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography, file de3e52b0-56f3-762d-e053-3705fe0a30e0
|
38
|
|
Does the margin width influence recurrence rate in liver surgery for hepatocellular carcinoma smaller than 5 cm?, file de3e52b3-7171-762d-e053-3705fe0a30e0
|
31
|
|
Free episomal and integrated HBV DNA In HBsAg-negative patients with intrahepatic cholangiocarcinoma, file de3e52b2-bd56-762d-e053-3705fe0a30e0
|
24
|
|
Obesity and liver cancer, file de3e52b2-933f-762d-e053-3705fe0a30e0
|
23
|
|
NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C, file de3e52b1-9027-762d-e053-3705fe0a30e0
|
22
|
|
Update of the statements on biology and clinical impact of occult hepatitis B virus infection, file de3e52b2-bb40-762d-e053-3705fe0a30e0
|
22
|
|
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV, file de3e52b1-3567-762d-e053-3705fe0a30e0
|
20
|
|
How infectious is the hepatitis B virus? Readings from the occult., file de3e52b1-9025-762d-e053-3705fe0a30e0
|
20
|
|
Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis, file de3e52b4-fa29-762d-e053-3705fe0a30e0
|
20
|
|
Behaviour of occult HBV infection in HCV-infected patients under treatment with direct-acting antivirals, file de3e52b1-c759-762d-e053-3705fe0a30e0
|
19
|
|
Occult hepatitis B virus infection, file de3e52ae-ac84-762d-e053-3705fe0a30e0
|
17
|
|
Case Report: Atrial Fibrillation After Intravenous Administration of Iodinated Contrast Medium in a Patient With Hepatocellular Carcinoma, file de3e52b2-a439-762d-e053-3705fe0a30e0
|
17
|
|
Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy, file de3e52b2-9ac5-762d-e053-3705fe0a30e0
|
16
|
|
Hepatitis B and C viruses and hepatocellular carcinoma, file 0fc8d31f-5d8d-42f8-934c-600e49332b57
|
15
|
|
Occult hepatitis B virus infection, file de3e52ae-a9d1-762d-e053-3705fe0a30e0
|
15
|
|
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study, file de3e52b0-dab1-762d-e053-3705fe0a30e0
|
15
|
|
Impact of Occult Hepatitis B Virus Infection on the Outcome of Chronic Hepatitis C., file de3e52ae-f4d3-762d-e053-3705fe0a30e0
|
12
|
|
Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma., file de3e52af-97e6-762d-e053-3705fe0a30e0
|
12
|
|
Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis., file de3e52b1-361f-762d-e053-3705fe0a30e0
|
12
|
|
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort., file de3e52b1-433f-762d-e053-3705fe0a30e0
|
12
|
|
Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis, file 048dce26-c2c1-4911-8f25-b66ef70ef630
|
11
|
|
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents., file de3e52b1-85aa-762d-e053-3705fe0a30e0
|
11
|
|
Potential feasibility of Atezolizumab-Bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors, file 192a2131-a764-4f39-aec6-93e51999cceb
|
8
|
|
Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity, file 91b45130-01f6-47e2-921f-f901e9e2771e
|
8
|
|
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel, file de3e52b0-d2de-762d-e053-3705fe0a30e0
|
7
|
|
Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepatitis B virus infection, file de3e52b0-0928-762d-e053-3705fe0a30e0
|
6
|
|
null, file de3e52b0-a513-762d-e053-3705fe0a30e0
|
6
|
|
Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care, file de3e52b0-db6e-762d-e053-3705fe0a30e0
|
6
|
|
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study, file de3e52b1-23ea-762d-e053-3705fe0a30e0
|
6
|
|
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients, file de3e52b1-fdbc-762d-e053-3705fe0a30e0
|
6
|
|
Occult hepatitis B virus infection predicts non-alcoholic steatohepatitis in severely obese individuals from Italy, file de3e52b2-aa22-762d-e053-3705fe0a30e0
|
6
|
|
null, file de3e52b3-275d-762d-e053-3705fe0a30e0
|
6
|
|
Hepatitis B viral replication influences the expression of natural killer cell ligands, file de3e52b0-18d7-762d-e053-3705fe0a30e0
|
5
|
|
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial., file de3e52b1-9029-762d-e053-3705fe0a30e0
|
5
|
|
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience, file de3e52b2-c7ff-762d-e053-3705fe0a30e0
|
5
|
|
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study, file 9eadd82b-4744-46d2-abcc-f63f3db41bde
|
4
|
|
Occult hepatitis B virus infection in hepatitis C virus negative chronic liver diseases, file d4c384e2-4575-42c8-91b8-d8e0d186adc8
|
4
|
|
Occult hepatitis b virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C, file de3e52ae-cdb1-762d-e053-3705fe0a30e0
|
4
|
|
Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection., file de3e52ae-d129-762d-e053-3705fe0a30e0
|
4
|
|
Case Report: Atrial Fibrillation After Intravenous Administration of Iodinated Contrast Medium in a Patient With Hepatocellular Carcinoma, file de3e52af-6823-762d-e053-3705fe0a30e0
|
4
|
|
Atrial fibrillation in patients with cirrhosis, file de3e52af-700a-762d-e053-3705fe0a30e0
|
4
|
|
Response to the high diagnostic characteristics of HBsAg level in differentiation of Hepatitis B clinical presentations: myth or truth?, file de3e52b0-daaf-762d-e053-3705fe0a30e0
|
4
|
|
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study, file de3e52b1-356a-762d-e053-3705fe0a30e0
|
4
|
|
Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance, file de3e52b3-966d-762d-e053-3705fe0a30e0
|
4
|
|
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients, file de3e52b4-b3bd-762d-e053-3705fe0a30e0
|
4
|
|
Occult hepatitis B virus infection in hepatitis C virus negative chronic liver diseases, file de3e52b5-2e52-762d-e053-3705fe0a30e0
|
4
|
|
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study, file e3ae2c8d-0384-4eb8-82cd-bfba7e614a9b
|
4
|
|
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort, file 0e017d27-eea8-42ac-92bd-6763dd04c0a7
|
3
|
|
Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia, file 3e10b8b2-fd58-489d-a284-50c1178a9c3f
|
3
|
|
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment, file a96f182b-8736-4b4a-9f51-83e78fde179f
|
3
|
|
TT virus has a ubiquitous diffusion in human body tissues: analyses of paired serum and tissue samples., file de3e52ae-bdeb-762d-e053-3705fe0a30e0
|
3
|
|
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C., file de3e52ae-fea9-762d-e053-3705fe0a30e0
|
3
|
|
Lack of the NS5B S282T mutation in HCV isolates from liver tissue of naive patients with HCV genotype-1b infection., file de3e52af-988a-762d-e053-3705fe0a30e0
|
3
|
|
The use of molecular assays in the management of viral hepatitis, file de3e52b0-1a4c-762d-e053-3705fe0a30e0
|
3
|
|
Flavocoxid exerts a potent antiviral effect against hepatitis B virus., file de3e52b1-39ec-762d-e053-3705fe0a30e0
|
3
|
|
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?, file de3e52b4-0a1b-762d-e053-3705fe0a30e0
|
3
|
|
Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease, file de3e52b5-6823-762d-e053-3705fe0a30e0
|
3
|
|
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3 infected patients within the Italian network VIRONET-C, file de3e52b5-764d-762d-e053-3705fe0a30e0
|
3
|
|
Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization, file f7bea910-473a-4f53-b36e-34e56ef78975
|
3
|
|
Occult hepatitis B virus infection predicts non-alcoholic steatohepatitis in severely obese individuals from Italy, file 6955ce1e-7031-4ed3-a66d-bce9005b060a
|
2
|
|
Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter, file d91eb586-5b37-49a4-a23f-fb2886adfe40
|
2
|
|
Expression of pre-S gene-encoded proteins in liver and serum during chronic hepatitis B virus infection in comparison to other markers of active virus replication, file de3e52ae-a01e-762d-e053-3705fe0a30e0
|
2
|
|
Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in 1-year follow-up study, file de3e52ae-b87c-762d-e053-3705fe0a30e0
|
2
|
|
Fibroscan: a new non-invasive method for evaluation of liver dysfunction in Turner syndrome, file de3e52ae-c396-762d-e053-3705fe0a30e0
|
2
|
|
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection., file de3e52ae-c90f-762d-e053-3705fe0a30e0
|
2
|
|
A 2010 update on occult hepatitis B infection., file de3e52ae-d033-762d-e053-3705fe0a30e0
|
2
|
|
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B., file de3e52ae-ec2b-762d-e053-3705fe0a30e0
|
2
|
|
Hepatitis B virus PreS/S gene variants: Pathobiology and clinical implications., file de3e52ae-f163-762d-e053-3705fe0a30e0
|
2
|
|
DEPRESSION AND BEHAVIORAL DISORDERS IN CHRONIC VIRAL HEPATITIS, file de3e52ae-f803-762d-e053-3705fe0a30e0
|
2
|
|
Hepatitis B virus basal core promoter mutations show lower replication fitness associated with cccDNA acetylation status, file de3e52b0-0922-762d-e053-3705fe0a30e0
|
2
|
|
Low prevalence of hepatitis B and hepatitis C virus serum markers in a cohort of pregnant women from Southern Italy, file de3e52b1-3a50-762d-e053-3705fe0a30e0
|
2
|
|
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study, file de3e52b1-4563-762d-e053-3705fe0a30e0
|
2
|
|
Integration of hepatitis B virus DNA in chronically infected patients assessed by Alu-PCR., file de3e52b1-d192-762d-e053-3705fe0a30e0
|
2
|
|
Monofocal hepatocellular carcinoma: How much does size matter?, file de3e52b4-31a3-762d-e053-3705fe0a30e0
|
2
|
|
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents., file de3e52b4-39c7-762d-e053-3705fe0a30e0
|
2
|
|
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis, file de3e52b4-fa2b-762d-e053-3705fe0a30e0
|
2
|
|
Cirrhotic Patients with Bacterial Infection and Negative Cultures Have a More Advanced Disease and an Increased Short-Term Mortality Rate, file de3e52b5-27ca-762d-e053-3705fe0a30e0
|
2
|
|
Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound‑detected liver nodules, file de3e52b5-3e8b-762d-e053-3705fe0a30e0
|
2
|
|
Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance, file 3157df58-e2e4-4ef6-a32b-9a1fa0aed24b
|
1
|
|
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward
elimination, file 64474820-d777-4fa5-97e8-01078358f0ea
|
1
|
|
Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients, file 962b46b3-3510-4c64-a5f0-bd79c685f7fb
|
1
|
|
Clinical virology of hepatitis B virus infection, file de3e52ae-a9d2-762d-e053-3705fe0a30e0
|
1
|
|
Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients., file de3e52ae-b7fc-762d-e053-3705fe0a30e0
|
1
|
|
What is the clinical impact of occult hepatitis B virus infection?, file de3e52ae-b872-762d-e053-3705fe0a30e0
|
1
|
|
Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis., file de3e52ae-bdf2-762d-e053-3705fe0a30e0
|
1
|
|
Correlates of total homocysteine plasma concentration in type 2 diabetes, file de3e52ae-c2ad-762d-e053-3705fe0a30e0
|
1
|
|
Is there a downgrading in the alert about the hepatitis B virus infection in Italy?, file de3e52ae-d03a-762d-e053-3705fe0a30e0
|
1
|
|
Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy, file de3e52ae-d125-762d-e053-3705fe0a30e0
|
1
|
|
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease, file de3e52ae-d126-762d-e053-3705fe0a30e0
|
1
|
|
Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection, file de3e52ae-d127-762d-e053-3705fe0a30e0
|
1
|
|
Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma., file de3e52ae-e9d0-762d-e053-3705fe0a30e0
|
1
|
|
NS3 genetic variability in hepatitis C virus genotype-1b isolates from liver specimens and blood samples of treatment naïve patients with chronic hepatitis C, file de3e52ae-ea42-762d-e053-3705fe0a30e0
|
1
|
|
Hepatitis B vaccination: are escape mutant viruses a matter of concern?, file de3e52ae-f199-762d-e053-3705fe0a30e0
|
1
|
|
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency., file de3e52ae-fc05-762d-e053-3705fe0a30e0
|
1
|
|
null, file de3e52af-08eb-762d-e053-3705fe0a30e0
|
1
|
|
The clinical significance of occult HBV infection, file de3e52af-8e18-762d-e053-3705fe0a30e0
|
1
|
|
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort, file de3e52b0-21a6-762d-e053-3705fe0a30e0
|
1
|
|
From current status to optimization of HCV treatment: Recommendations from an expert panel, file de3e52b0-db70-762d-e053-3705fe0a30e0
|
1
|
|
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?, file de3e52b1-8e69-762d-e053-3705fe0a30e0
|
1
|
| Totale |
671 |